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Abstract
Background: Vascular cognitive impairment (VCI), compared to vascular dementia (VD), has a broader definition
and highlights the effect of vascular disease in dementia, and stroke seems play an important role in the development
of VCI. However, not all patients with brain infarcts suffer from VCI; unique risk factors appear to cause such progression.
This study aimed to find potential risk factors of vascular cognitive impairment among patients with brain infarcts.
Methods: Thirty-seven dementia patients and 74 brain infarction patients were included; all had infarcts in both basilar
ganglia. The frequencies of risk factors, such as age, hypertension, and hyperlipidemia, were compared between
the two groups.
Results: The incident rate of hyperlipidemia in the patients with dementia was 35.14%, which was significantly
lower than that in the patients with infarction (59.46%, P = 0.015). In the dementia group, there was a positive
correlation between the ratio of apoprotein B (apoB)/low density lipoprotein (LDL) and the Mini Mental State
Examination (MMSE) score (R = 0.411, P = 0.011).
Conclusion: Our study indicated that the ratio of apoB/LDL may be a potential clinical index for vascular
cognitive impairment.
Keywords: Vascular dementia, Vascular cognitive impairment, Stroke, MMSE, apoprotein B, Low density
lipoprotein
Background
Vascular dementia (VD) is a type of dementia that re-
sults from strokes destroying the brain areas important
for memory and intelligence, comprises at least 20% of
dementia cases, and is the second most common cause
of dementia, after Alzheimer’s disease (AD) [1]. How-
ever, it is sometimes difficult to differentiate VD and
AD. In the early 90s, the diagnostic criteria of VD were
mainly based on those of AD’s, which emphasized im-
pairment of memory and activities of daily living [2].
The criteria did not take into full consideration the ef-
fects of cerebrovascular lesions on cognitive impairment;
However, several clinical-pathological studies have
highlighted the role of cerebrovascular disease, not only
as a primary cause of vascular dementia, but also as a
modifier of the expression of dementia caused by other
factors, such as AD [1, 3]. Moreover, new experiments
have revealed functional and pathogenic synergy be-
tween neurons, glia, and vascular cells [4–6], providing a
new framework to evaluate how alterations in cerebral
blood vessels could contribute to the neuronal dysfunc-
tion underlying cognitive impairment. To highlight the
vascular nature of this cognitive deficit, the term vascu-
lar cognitive impairment (VCI) was introduced to better
reflect the full range of cognitive alterations resulting
from vascular factors [7]. VCI has been widely accepted
and is currently defined as “a syndrome with evidence
of clinical stroke or subclinical vascular brain injury
and cognitive impairment affecting at least one cogni-
tive domain” [1]; vascular dementia is the most severe
form of VCI.
Compared with AD, VCI is less well researched; there
are many studies about potential risk factors for AD,
whereas research about VCI risk factors is limited. The
construct of multi-infarct dementia, by attributing cog-
nitive impairment to multiple strokes, enables preven-
tion of cognitive impairment by controlling risk factors
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for stroke [8], such as hypertension, diabetes, smoking,
and hyperlipidemia. However, not all patients with brain
infarcts suffer from VCI; unique risk factors appear to
cause such progression. This study aims to evaluate po-
tential risk factor for VCI in patients with brain infarcts.
Methods
Study samples
In the present study 111 patients were included who were
the inpatients of the Neurologic Department in Shengjing
Hospital of China Medical University from 2010 to 2015.
All patients underwent magnetic resonance examination,
and their magnetic resonance imaging showed infarcts in
both basilar ganglia with or without infarcts in other brain
areas. Based on the presence or absence of cognitive im-
pairment, the 111 patients were divided into two groups:
dementia group (37 patients) and infarction group (74 pa-
tients). The 37 patients in the dementia group were all
underwent a Mini Mental State Examination (MMSE),
and diagnosed as VCI, based on the diagnosis criteria
provided by Rodríguez García [9]. Exclusion criteria:
disorders severe enough to cause cognitive impairment,
such as major depression, intracranial neoplasia, sub-
dural hematoma, chronic hydrocephalus, and intracra-
nial infection. The 74 patients in the infarction group
had no cognitive impairment.
Definition of risk factors
Smoking
Smoking was defined as at least one cigarette per day
and more than one year smoking history. Hypertension:
systolic blood pressure ≥140 mmHg and/or diastolic
blood pressure ≥90 mmHg. Hyperlipidemia: elevated
blood lipid, defined as LDL >3.37 mmol/L and/or TG
>1.69 mmol/L. Diabetes mellitus (DM): with a history of
diagnosed DM or DM diagnosed by endocrinologists of
our hospital based on clinical evidence. Vitamin B12
(VitB12) deficiency: serum VitB12 < 180 pg/mL. Folic
acid deficiency: serum folic acid <3.1 ng/mL. Encephalo-
malacia foci, encephalatrophy and leukoaraiosis: all MR
imagine were checked by experienced radiologists,
and the definition of Malacia foci, encephalatrophy
and leukoaraiosis were based on their diagnosis.
Laboratory measurements
All patients were required to fast overnight. Blood sam-
ples were collected in the following morning. Blood
sugar, blood lipids and other biochemical indicators in
the serum were measured by using an automatic, quality
standardized, biochemical analyzer.
MMSE
The Mini-Mental State Examination [10] is the most com-
monly used bedside test of cognition, which is dominated
by language-based tests, and the examination tests mem-
ory, visuoperceptual and executive functions less thor-
oughly; Several studies have demonstrated its diagnostic
utility for dementia in clinical practice [11, 12].
Statistical analysis
Data are shown as mean ± SD or percentage. Welch’s t
test was used to compare the mean values in the 2
groups; P < 0.05 indicated statistical significance. Logistic
regression was used to find potential independent risk
factors. Further, linear regression was used to describe
the relationship among any potential risk factors and
MMSE score, and Durbin-Waston test was used to
adjust the positive result.
Results
As shown in Table 1, the incidence rate of hyperlipid-
emia in the dementia group (35.14%) was significantly
lower than that in the infarction group (59.46%, P =
0.015), and the other risk factors, such as age, sex,
smoke, had no significantly difference between two
groups. And the logistic regression shows that hyperlip-
idemia is not the independent risk factor of VCI in
infarction patients (Table 2).
Subclasses of blood lipids are listed in Table 3; The
cholesterol (CHOL), TG, LDL, and apolipoprotein A-I,
apolipoprotein B (apoB) levels of the patients in the
dementia group values were significantly lower than
those of the patients in the infarction group.
But logistic regression also found that the above five
lipids index were not independently associated with the
VCI study group (Table 4).
When compared the five lipids index with MMSE
score in the dementia group, there were no significantly
Table 1 Comparison of demographic and clinical characteristics
of the two study groups
Dementia Infarction P value
Number 37 74
Age 70.62 ± 9.95 70.82 ± 12.04 0.93
Sex F: 37.84% F: 45.95% 0.421
M: 62.16% M: 54.05%
Smoke (%) 16.22 27.03 0.208
Hypertension (%) 72.97 71.62 0.882
Hyperlipidemia (%) 35.14 59.46 0.015
DM (%) 27.03 25.68 0.88
VitB12 deficiency (%) 32.43 18.92 0.115
Folic acid deficiency (%) 13.51 5.41 0.143
Foci of malacia (%) 29.73 20.27 0.271
Encephalatrophy (%) 81.08 66.22 0.105
Leukoaraiosis (%) 75.68 66.22 0.312
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correlation between them, however, we found that the
apoB/LDL ratio was positively related to the MMSE
score (R = 0.411, P = 0.011, Fig. 1, Table 5), and the linear
regression demonstrated a linear relationship between
the ratio of apoB/LDL and the MMSE score (R2 = 0.169,
P = 0.011, Table 6), but according to Durbin-Waston
(DW) test [13], the DW value approaching 0 indicated
positive auto-correlation, therefore this result has no
statistical significance (DW= 0.451, Table 6).
Discussion
The present study showed two interesting findings: 1)
Lipid levels of the dementia patients were lower than
those of the infarction patients in our study; 2) The
apoB/LDL ratio appeared to be positively related to the
MMSE score in the dementia patients.
Hyperlipidemia is abnormally elevated levels of any or
all lipids and/or lipoproteins in the blood. Based on the
density, lipoproteins consist of many subtypes, including
LDL, very low density lipoprotein (VLDL), intermediate
low density lipoprotein (ILDL), high density lipoprotein
(HDL), and chylomicron (CM). A different density deter-
mines a different fate of the particle and its influence on
metabolism. Among these lipoproteins, LDL is generally
considered a “bad” lipoprotein, meaning the strongest
causative risk factor for atherosclerosis [14]. According
to the ‘response-to-retention hypothesis’ [15], LDL is
bound and retained by extracellular matrix components;
undergoes a series of modifications in the arterial wall,
including oxidation, lipolysis, and proteolysis; fuses
together; and over time, increasing quantities of LDL
aggregate in the arterial wall, triggering a cascade of in-
flammatory and apoptotic responses. The aforemen-
tioned progress is called atherogenesis, which leads to
several cardiovascular diseases.
Furthermore, studies have suggested that cardiovascu-
lar risks contribute to VD, cognitive impairment and
AD, and hyperlipidemia is one of the atherogenic factors
among those cardiovascular risks [1, 16, 17]. However,
not all lipoproteins and lipids are harmful, and even the
“bad” lipoprotein, LDL, is essential for physiologic needs.
Several studies found no relationship between hyperlip-
idemia and cognitive impairment [18, 19], and some
studies reported potential benefits of lipoproteins and
lipids. Ledesma [20] demonstrated that cholesterol loss
during aging occurs in rodents’ and humans’ hippocam-
pus, and Mauricio’s [21] study suggested that this loss
would contribute to cognitive decay in the aged. Reyn-
olds [22] suggested that in humans, higher apoB and
total cholesterol levels were advantageous to cognitive
health, though effects diminished by age 65. In addition,
one study even demonstrated that high total cholesterol
levels in late life were associated with a reduced risk of
dementia [23]. Our study found that the percentage of
hyperlipidemia in the dementia group was lower than
that in the infarction group; although, this does not
prove that hyperlipidemia is a protective factor for vas-
cular dementia, considered together with above studies,
lipids appear to have complex effects in cognitive health.
Apolipoproteins are proteins that bind lipids to form
lipoproteins. They transport lipids through the lymphatic
and circulatory systems. Apolipoprotein B100 (apoB100),
one of the primary apolipoproteins, which is synthesized
in the liver, and it is an essential apolipoprotein of
Table 2 Variables in the equation
B S.E. Wald df Sig. Exp(B)
lipid −0.996 0.418 5.681 1 0.017 0.369
Constant −0.223 0.274 0.664 1 0.415 0.8
Table 3 Subtypes of lipids in two groups
Dementia Infarction P value
CHOL (mmol/l) 4.30 ± 0.86 4.82 ± 0.90 0.004
TG (mmol/l) 1.22 ± 0.51 1.55 ± 1.07 0.032
HDL (mmol/l) 1.11 ± 0.4 1.13 ± 0.25 0.770
LDL (mg/dl) 1.08 ± 0.31 1.26 ± 0.35 0.006
apoA-I (mg/dl) 1.13 ± 0.19 1.23 ± 0.27 0.039
apoB (mg/dl) 0.91 ± 0.22 1.05 ± 0.27 0.005
Table 4 Variables in the equation
B S.E. Wald df Sig. Exp(B)
TG −0.634 0.402 2.489 1 0.115 0.530
Chol 0.511 0.825 0.384 1 0.536 1.667
LDL −1.944 2.172 0.801 1 0.371 0.143
ApoA-I −2.171 1.078 4.057 1 0.044 0.114
ApoB −1.004 2.411 0.173 1 0.677 0.366
Constant 3.639 1.575 5.335 1 0.021 38.052
Fig. 1 Scatter diagram of the ratio apoB/LDL ratio and MMSE score
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VLDL, ILDL, and LDL. Because LDL persists longer in
the plasma than VLDL and IDL, 90% or more of all
apoB100 is associated with LDL. Therefore, many stud-
ies consider apoB the same risk factor as LDL [24–26].
However, apoB is simply a transportation molecule,
and LDL is not the only passenger, especially in humans.
The intestine synthesizes a truncated form of apolipo-
protein B (apoB48), which is the essential apolipoprotein
of CM. In addition, Neda’s [27] study demonstrated evi-
dence of no association of apoB polymorphisms (XbaI)
with obesity and serum lipid levels, indicating that the
LDL and apoB may not match with each other in quan-
tity. Furthermore, the discordance between apoB and
LDL may not be a rare clinical phenomenon [28]; an-
other study [29] showed that the superiority of apoB
and LDL for cardiovascular risk assessment is most evi-
dent when LDL and apoB are discordant, and the
discordance, LDL > apoB, was associated with insulin
resistance, smaller LDL particle size, increased systemic
inflammation and lower circulating levels of serum
lipids, whereas discordance in the other direction,
apoB > LDL, was associated with larger LDL particle
size, elevated levels of lipoprotein a, and lipoprotein-
associated phospholipase A2. Moreover, small size LDL
particles may be one of multiple atherogenic triggers
for the pathology of AD [30], and systemic inflamma-
tion and insulin resistance are also considered potential
risk factors of dementia [31–33].
Of note, apoB itself might also have some benefits: a
previous study [34] demonstrated that apoB, either iso-
lated or in LDL, exhibits activity of both phospholipase
A1 and phospholipase A2, and apoB may play a protect-
ive role by removing oxidized fatty acids from the sn-2
position of LDL phospholipids to reduce its cellular up-
take. ApoB might also contribute to innate defense;
studies reported that apoB100 and apoB48 could prevent
Staphylococcus aureus (S. aureus) infection by binding
and sequestering S. aureus and antagonizing quorum
sensing, thereby reducing virulence [35, 36].
In addition, higher levels of LDL may contribute to al-
terations in brain tissue structure, particularly white
matter integrity, leading to cognitive impairment and
dementia [37]. Notably, Wang [38], using ldlr−/− mice,
showed that higher levels of LDL, together with in-
creased intracellular lipid deposition, impaired spatial
cognition, decreased synapse density, and increased
neuronal apoptosis in the hippocampus. In light of the
above insights about apoB, the ratio of apoB/LDL ap-
pears a reasonable clinical index; higher apoB and lower
LDL may benefit the cognitive health in VCI patients.
This question warrants consideration: How might
serum lipoprotein and apolipoprotein contribute to the
development of VCI? Normally, changes in serum chol-
esterol do not affect brain cholesterol homeostasis, and
there seems to be no relevant cholesterol flux from the
periphery into the brain [39]. Transport of serum lipids
through blood-brain barrier (BBB) may be explained by
the conversion of cholesterol to oxysterols [37], choles-
terol may undergo an oxidative process that allows the
resultant serum-derived 27-hydroxycholesterol (27-OHC)
and brain-derived 24S-hydroxycholesterol (24S-OHC) to
freely diffuse into the brain driven by concentration gradi-
ents [40]; 27-OHC and 24S-OHC have been considered
biomarkers for certain neurodegenerative disease includ-
ing AD [41]. In addition, dyslipidemia may alter BBB func-
tion in AD [42], contributing to the transportation of
inflammatory lipids from the blood [6]. Further, studies
have found ApoB-100 protein in the membrane microdo-
mains of primary brain endothelial cells [43, 44]. Using
the LDL-receptor binding domain of apoB could be an
effective way to deliver recombinant proteins across the
BBB, and such an approach can be used to treat a neuro-
degenerative disease [45, 46].
This study has some limitations. First, compared fewer
samples, more patients should be studied. Second, the
MMSE has not been adjusted for the lack of the educa-
tional experience of some patients, which this could lead
to a certain error. Third, without other examinations,
such as the Hachinski Ischemic Score, we could not de-
fine the subclass of dementia, so we used the broader
concept: VCI. However, our sample only included a
small subclass of VCI. Most patients were likely cases of
multi-infarct dementia, according to the MRI findings
and diagnostic criteria provided by Rodríguez García [9];
this may affect the generalizability of our results. Fourth,
the age of the infarction group is relatively young com-
pared with dementia group, although P = 0.93 > 0.05,
with no statistical significance, but it still can’t exclude
the possibility that the infarction group would develop
cognitive impairment at a later life. Fifth, in our sample,
Table 5 Correlations
MMSE apoB/LDL
MMSE Pearson Correlation 1 0.411a
Sig. (2-tailed) 0.011
N 37 37
apoB/LDL Pearson Correlation 0.411a 1
Sig. (2-tailed) 0.011
N 37 37
aCorrelation is significant at the 0.05 level (2-tailed)
Table 6 Model summaryb





1 0.411a .169 0.146 3.88304 0.451
aPredictors: (Constant), apoB/LDL
bDependent Variable: MMSE
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the infarcts were multi-focal and some had encephalo-
malacia foci, but most had a scattering lacunar infarcts;
consequently, it was difficult to measure the area of
infarcts, so we could only compare the frequency of
patients with encephalomalacia foci, encephalatrophy,
and leukoaraiosis between the two groups, but still the
lack of cognitive impairment in the infarction group
could just be the result of insufficient lesions. Sixth, due
to the R value is more than 0.4 but less than 0.8, the
positive correlation between the ratio of apoB/LDL and
MMSE score is moderated, on the one hand, the low R
value means that the model of apoB/LDL could not fully
explain the change of MMSE score, there must be other
factors, and it could lead to the negative result of DW
test, so our finding was not comprehensive, but from
current data, we couldn’t find the other factors, more
studies should be done, on the other hand, yet, it at least
means that the model of apoB/LDL play a certain role in
the change of MMSE score.
Conclusion
In summary, lipid may be the key factor causing VCI in
the infarction patients, hyperlipidemia was less common
in VCI compared with stroke without dementia, and to
our best knowledge, this article is the first ever to
present the ratio of apoB/LDL as a possible clinical
index for VCI. Further studies should be performed
based on the new insights this study of VCI provides.
Additional file
Additional file 1: Original data set. (XLS 41 kb)
Abbreviations
24S-OHC: 24S-hydroxycholesterol; 27-OHC: 27-hydroxycholesterol;
AD: Alzheimer’s disease; apoB: apoprotein B; apoB100: apolipoprotein B100;
apoB48: apolipoprotein B48; BBB: Blood-brain barrier; CHOL: Cholesterol;
CM: Chylomicron; DM: Diabetes mellitus; DW: Durbin-Waston; HDL: High
density lipoprotein; ILDL: Intermediate low density lipoprotein; LDL: Low density
lipoprotein; MMSE: Mini mental state examination; S. Aureus: Staphylococcus
aureus; VCI: Vascular cognitive impairment; VD: Vascular dementia;
VitB12: Vitamin B12; VLDL: Very low density lipoprotein
Acknowledgements
Thanks to all those who have lent us hands in the course of this paper. First
of all, we would like to take this opportunity to show our sincere gratitude
to Dr. Zhijie Li, who has given us so much useful advices on our writing, and
has tried her best to improve our paper. Secondly, we want to express our
gratitude to our colleagues who help us in the data collection.
Funding
Current study was supported by Natural Science Foundation of Liaoning
Province, Award number: 201602855.
Availability of data and materials
All data generated or analyzed during this study are included in this published
article and its supplementary information files [see Additional file 1].
Authors’ contributions
Fei Tan supervised the data collection, helped to revise the manuscript, and
agreed to be accountable for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part of the work were appropriately
investigated and resolved. Cheng Qian was responsible for the design of the
study, was the principal investigator and drafted the manuscript, and revised




The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study has proved by the Ethics Committee of Shengjing Hospital of
China Medical University. This study was a retrospective study, there were
no consent needed to participate.
Received: 26 July 2016 Accepted: 17 November 2016
References
1. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive
impairment and dementia: a statement for healthcare professionals from
the american heart association/american stroke association. Stroke. 2011;42:
2672–713.
2. Roman G, Takemici T, Erkinjuntti T, et al. Vascular dementia: diagnostic
criteria for research studies: report of the NINDS-AIREN international
workshop. Neurology. 1993;43:250–60.
3. Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease
in autopsy confirmed neurodegenerative disease cases in the National
Alzheimer’s Coordinating Centre. Brain. 2013;136:2697–706.
4. Iadecola C. The overlap between neurodegenerative and vascular factors in
the pathogenesis of dementia. Acta Neuropathol. 2010;120:287–96.
5. Quaegebeur A, Lange C, Carmeliet P. The neurovascular link in health and
disease: molecular mechanisms and therapeutic implications. Neuron. 2011;
71:406–24.
6. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s
disease and other disorders. Nat Rev Neurosci. 2011;12:723–38.
7. Hachinski V, Bowler J. Vascular dementia. Neurology. 1993;43:2159–60.
8. Hachinski V, Lassen N, Marshall J. Multi-infarct dementia. A cause of mental
deterioration in the elderly. Lancet. 1974;2:207–10.
9. Rodríguez García PL, Rodríguez GD. Diagnosis of vascular cognitive
impairment and its main categories. Neurologia. 2015;30:223–39.
10. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”. A practical method
for grading the cognitive state of patients for the clinician. J Psychiatr Res.
1975;12:189–98.
11. Hancock P, Larner AJ. Diagnostic utility of the informant questionnaire on
cognitive decline in the elderly (IQCODE) and its combination with the
Addenbrooke’s cognitive examination-revised (ACE-R) in a memory clinic-
based population. Int Psychogeriatr. 2009;21:526–30.
12. Hancock P, Larner AJ. Test Your Memory (TYM) test: diagnostic utility in a
memory clinic population. Int J Geriatr Psychiatry. 2011;26:976–80.
13. Durbin J, Watson GS. Testing for serial correlation in least squares regression.
I Bio28metrika. 1950;37:409–28.
14. Castelli WP, Anderson K, Wilson PW, Levy D. The Framingham Study. Lipids
and risk of coronary heart disease. Ann Epidemiol. 1992;2:23–8.
15. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis.
Arterioscler Thromb Vasc Biol. 1995;15:551–61.
16. Solomon A, Kareholt I, Ngandu TBM, et al. Serum cholesterol changes after
midlife and late-life cognition, twenty-one-year follow-up study. Neurology.
2007;68:751–6.
17. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum
cholesterol and increased risk of Alzheimer’s and vascular dementia three
decades later. Dement Geriatr Cogn Disord. 2009;28:75–80.
Qian and Tan BMC Neurology  (2016) 16:243 Page 5 of 6
18. Okusaga O, Stewart MC, Butcher I, et al. Smoking, hypercholesterolaemia
and hypertension as risk factors for cognitive impairment in older adults.
Age Ageing. 2013;42:306–11.
19. Stewart R, White LR, Xue QL, Launer LJ. Twenty-six-year change in total
cholesterol levels and incident dementia: the Honolulu-Asia Aging Study.
Arch Neurol. 2007;64:103–7.
20. Ledesma MD, Martin MG, Dotti CG. Lipid changes in the aged brain: effect
on synaptic function and neuronal survival. Prog Lipid Res. 2012;51:23–35.
21. Martin MG, Ahmed T, Korovaichuk A, et al. Constitutive hippocampal
cholesterol loss underlies poor cognition in old rodents. EMBO Mol Med.
2014;6:902–17.
22. Reynolds CA, Gatz M, Prince JA, Berg S, Pedersen NL. Serum lipid levels and
cognitive change in late life. J Am Geriatr Soc. 2010;58:501–9.
23. Mielke MM, Zandi PP, Sjogren M, et al. High total cholesterol levels in late
life associated with a reduced risk of dementia. Neurology. 2005;64:1689–95.
24. Andrikoula M, McDowell IFW. The contribution of apoB and apoA1
measurements to cardiovascular risk assessment. Diabetes Obes Metab.
2008;10:271–8.
25. Du T, Zhang J, Yuan G, et al. Nontraditional risk factors for cardiovascular
disease and visceral adiposity index among different body size phenotypes.
Nutr Metab Cardiovasc Dis. 2015;25:100–7.
26. Nomikos T. Panagiotakos D2,3, Georgousopoulou E, et al. Hierarchical
modelling of blood lipids’ profile and 10-year (2002–2012) all cause
mortality and incidence of cardiovascular disease: the ATTICA study.
Lipids Health Dis. 2015;14:108.
27. Bogari NM, Abdel-Latif AM, Hassan MA, et al. No association of apolipoprotein
B gene polymorphism and blood lipids in obese Egyptian subjects. J Negat
Results Biomed. 2015;14:7.
28. Cole TG, Contois JH, Csako G, et al. Association of apolipoprotein B and
nuclear magnetic resonance spectroscopy-derived LDL particle number
with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein
and Vascular Diseases Division Working Group on Best Practices. Clin Chem.
2013;59:752–70.
29. Varvel SA, Dayspring TD, et al. Discordance between apolipoprotein B and
low-density lipoprotein particle number is associated with insulin resistance
in clinical practice. J Clin Lipidol. 2015;9:247–55.
30. Vikarunnessa S, Weiner MF, Vega GL. LDL phenotype in subjects with mild
cognitive impairment and Alzheimer’s disease. J Alzheimers Dis. 2013;36:571–5.
31. Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia.
Curr Neurol Neurosci Rep. 2007;7:373–80.
32. van Himbergen TM, Beiser AS, Ai M, et al. Biomarkers for insulin resistance
and inflammation and the risk for all-cause dementia and alzheimer disease:
results from the Framingham Heart Study. Arch Neurol. 2012;69:594–600.
33. Enciu AM, Popescu BO. Is there a causal link between inflammation and
dementia? Biomed Res Int. 2013;2013:316495.
34. Reisfeld N, Lichtenberg D, Dagan A, Yedgar S. Apolipoprotein B exhibits
phospholipase A1 and phospholipase A2 activities. FEBS Lett. 1993;315:267–70.
35. Peterson MM, Mack JL, Hall PR, Alsup AA, Alexander SM, Sully EK, et al.
Apolipoprotein B is an innate barrier against invasive Staphylococcus
aureus infection. Cell Host Microbe. 2008;4:555–66.
36. Elmore BO. Triplett KD1, Hall PR1. Apolipoprotein B48, the Structural
Component of Chylomicrons, Is Sufficient to Antagonize Staphylococcus
aureus Quorum-Sensing. PLoS One. 2015;10:e0125027.
37. Williams VJ, Leritz EC, Shepel J, et al. Interindividual variation in serum cholesterol
is associated with regional white matter tissue integrity in older adults. Hum
Brain Mapp. 2013;34:1826–41.
38. Wang SH, Huang Y, Yuan Y, et al. LDL receptor knock-out mice show
impaired spatial cognition with hippocampal vulnerability to apoptosis
and deficits in synapses. Lipids Health Dis. 2014;13:175.
39. Dietschy JM, Turley SD. Cholesterol metabolism in the central nervous
system during early development and in the mature animal. J Lipid Res.
2004;45:1375–97.
40. Babiker A, Dzeletovic S, Wiklund B, et al. Patients with atherosclerosis may
have increased circulating levels of 27-hydroxycholesterol and cholestenoic
acid. Scand J Clin Lab Invest. 2005;65(5):365–75.
41. Heverin M, Bogdanovic N, Lutjohann D, et al. Changes in the levels of
cerebral and extracerebral sterols in the brain of patients with Alzheimer’s
disease. J Lipid Res. 2004;45:186–93.
42. Bowman GL, Kaye JA, Quinn JF. Dyslipidemia and blood-brain barrier
integrity in Alzheimer’s disease. Curr Gerontol Geriatr Res. 2012;2012:184042.
43. Dodelet-Devillers A, Cayrol R, van Horssen J, et al. Functions of lipid raft
membrane microdomains at the blood–brain barrier. J Mol Med (Berl). 2009;
87:765–74.
44. Lénárt N, Walter FR, Bocsik A, et al. Cultured cells of the blood-brain barrier
from apolipoprotein B-100 transgenic mice: effects of oxidized low-density
lipoprotein treatment. Fluids Barriers CNS. 2015;12:17.
45. Spencer BJ, Verma IM. Targeted delivery of proteins across the blood-brain
barrier. Proc Natl Acad Sci U S A. 2007;104:7594–9.
46. Spencer B, Marr RA, Gindi R, et al. Peripheral delivery of a CNS targeted,
metalo-protease reduces aβ toxicity in a mouse model of Alzheimer’s
disease. PLoS One. 2011;6:e16575.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Qian and Tan BMC Neurology  (2016) 16:243 Page 6 of 6
